{"id":1592,"date":"2016-11-30T12:20:50","date_gmt":"2016-11-30T12:20:50","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=1592"},"modified":"2021-10-12T11:08:09","modified_gmt":"2021-10-12T05:38:09","slug":"the-snippet-weaponized-antibodies-use-new-tricks-to-fight-cancer","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/the-snippet-weaponized-antibodies-use-new-tricks-to-fight-cancer","title":{"rendered":"The next generation of &#8216;weaponized antibody&#8217; therapies"},"content":{"rendered":"<p style=\"text-align: justify;\">Efforts to develop antibodies that can ferry drugs into cancer cells and minimize damage to healthy tissue are gathering steam. The next generation of these \u2018weaponized antibody\u2019 therapies, called antibody\u2013drug conjugates (ADCs), is working its way through clinical trials. The concept that underlies these drugs is simple, as they re-purpose an antibody as a vehicle to deliver a toxic drug into a cancer cell. When the antibody in an ADC seeks out and docks onto a tumour cell, the cell takes it up and cleaves the molecular links that bind the drug to the antibody. This frees the drug to kill the cell from within. Researchers have been chasing ADCs for decades. The US Food and Drug Administration has approved three, but one was subsequently withdrawn from the market amid concerns that it was not effective and posed safety risks. The other two have met a happier fate: sales of Adcetris (brentuximab vedotin), approved in 2011 to treat lymphoma, and Kadcyla (trastuzumab emtansine), approved in 2013 to treat breast cancer, have been encouraging.<\/p>\n<p>To learn more, click <a href=\"http:\/\/www.nature.com\/news\/weaponized-antibodies-use-new-tricks-to-fight-cancer-1.21062\">Antibody\u2019 Therapies<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Efforts to develop antibodies that can ferry drugs into cancer cells and minimize damage to healthy tissue are gathering steam. The next generation of these \u2018weaponized antibody\u2019 therapies, called antibody\u2013drug conjugates (ADCs), is working its way through clinical trials. The concept that underlies these drugs is simple, as they re-purpose an antibody as a vehicle [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1593,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[41],"tags":[666,78,127,137,667,595],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-1592","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-snippets","tag-antibodies","tag-antibody-drug-conjugates","tag-breast-cancer","tag-cancer","tag-lymphoma","tag-usfda","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Antibody-drug conjugates (ADCs) and Their Therapeutic Advantage<\/title>\n<meta name=\"description\" content=\"Efforts to develop antibodies that can ferry drugs into cancer cells and minimize damage to healthy tissue are gathering steam.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/the-snippet-weaponized-antibodies-use-new-tricks-to-fight-cancer\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Antibody-drug conjugates (ADCs) and Their Therapeutic Advantage\" \/>\n<meta property=\"og:description\" content=\"Efforts to develop antibodies that can ferry drugs into cancer cells and minimize damage to healthy tissue are gathering steam.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/the-snippet-weaponized-antibodies-use-new-tricks-to-fight-cancer\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2016-11-30T12:20:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-10-12T05:38:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/11\/09022643\/adc.png\" \/>\n\t<meta property=\"og:image:width\" content=\"773\" \/>\n\t<meta property=\"og:image:height\" content=\"827\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Antibody-drug conjugates (ADCs) and Their Therapeutic Advantage","description":"Efforts to develop antibodies that can ferry drugs into cancer cells and minimize damage to healthy tissue are gathering steam.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/the-snippet-weaponized-antibodies-use-new-tricks-to-fight-cancer","og_locale":"en_US","og_type":"article","og_title":"Antibody-drug conjugates (ADCs) and Their Therapeutic Advantage","og_description":"Efforts to develop antibodies that can ferry drugs into cancer cells and minimize damage to healthy tissue are gathering steam.","og_url":"https:\/\/www.delveinsight.com\/blog\/the-snippet-weaponized-antibodies-use-new-tricks-to-fight-cancer","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2016-11-30T12:20:50+00:00","article_modified_time":"2021-10-12T05:38:09+00:00","og_image":[{"width":773,"height":827,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/11\/09022643\/adc.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/the-snippet-weaponized-antibodies-use-new-tricks-to-fight-cancer","url":"https:\/\/www.delveinsight.com\/blog\/the-snippet-weaponized-antibodies-use-new-tricks-to-fight-cancer","name":"Antibody-drug conjugates (ADCs) and Their Therapeutic Advantage","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-snippet-weaponized-antibodies-use-new-tricks-to-fight-cancer#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-snippet-weaponized-antibodies-use-new-tricks-to-fight-cancer#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/11\/09022643\/adc.png","datePublished":"2016-11-30T12:20:50+00:00","dateModified":"2021-10-12T05:38:09+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Efforts to develop antibodies that can ferry drugs into cancer cells and minimize damage to healthy tissue are gathering steam.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/the-snippet-weaponized-antibodies-use-new-tricks-to-fight-cancer"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/the-snippet-weaponized-antibodies-use-new-tricks-to-fight-cancer#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/11\/09022643\/adc.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/11\/09022643\/adc.png","width":773,"height":827},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/11\/09022643\/adc-280x300.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">antibodies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Antibody-Drug Conjugates<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Breast Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">lymphoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">USFDA<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">antibodies<\/span>","<span class=\"advgb-post-tax-term\">Antibody-Drug Conjugates<\/span>","<span class=\"advgb-post-tax-term\">Breast Cancer<\/span>","<span class=\"advgb-post-tax-term\">Cancer<\/span>","<span class=\"advgb-post-tax-term\">lymphoma<\/span>","<span class=\"advgb-post-tax-term\">USFDA<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 9 years ago","modified":"Updated 4 years ago"},"absolute_dates":{"created":"Posted on Nov 30, 2016","modified":"Updated on Oct 12, 2021"},"absolute_dates_time":{"created":"Posted on Nov 30, 2016 12:20 pm","modified":"Updated on Oct 12, 2021 11:08 am"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1592","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=1592"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1592\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/1593"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=1592"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=1592"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=1592"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=1592"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=1592"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}